The Next PCSK-9 Pricing Debate: PBM Says Outcomes Data Should Mean Deeper Discount
Executive Summary
Express Scripts expects to negotiate a lower price per patient for Amgen’s Repatha assuming the drug shows benefits in a 27,500-patient outcomes trial. Critics of the PBM and its practices, however, may help industry push back against the idea that greater benefit means lower prices.
You may also be interested in...
Praluent’s Price Cut: Testing The Tech Model For Drug Pricing
It may be more accident than design, but Sanofi and Regeneron are applying a tried and true pricing model to Praluent. Just ask tech companies.
Trump’s Drug Pricing Remarks: A Gambit For Industry Self-Restraint?
Comments during recent interview shows president-elect continues to view drug pricing as populist issue, revives speculation he may take action to control prices.
The Future Of Specialty Drug Pricing
The rise of specialty drugs is causing major shifts in pharmaceutical spending. A new report by Datamontior Healthcare outlines the pricing trends that are shaping this fast-growing segment (article free with registration).